Lux Ventures II Sidecar LP

CIK 00013439433 companiesNEW YORK, NY

SEC Profile

Transactions

Companies

Filings

CIK

0001343943

Recent Transactions

19 trades

Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
5% Convertible Subordinated Promissory Note
2016-10-13→ 0 total
Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
Common Stock
2016-10-13+118,606→ 656,465 total
Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
Series A Preferred Stock
2016-10-13−219,916→ 0 total
Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
5% Convertible Subordinated Promissory Note
2016-10-13→ 0 total
Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
Common Stock
2016-10-13+219,916→ 537,859 total
Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
Common Stock
2016-10-13$6.40/sh+131,719→ 788,184 total
Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
Series B Preferred Stock
2016-10-13−118,606→ 0 total
Conversion
EVERSPIN TECHNOLOGIES INC.$MRAM
Common Stock
2016-10-13$6.40/sh+89,946→ 878,130 total
Purchase
EVERSPIN TECHNOLOGIES INC.$MRAM
Common Stock
2016-10-13$8.00/sh+137,420→ 1,015,550 total
Conversion
GENOCEA BIOSCIENCES, INC.
Common Stock
2014-02-10+269,561→ 1,237,683 total
Conversion
GENOCEA BIOSCIENCES, INC.
Series A Preferred Stock
2014-02-10−8,393,754→ 0 total
Conversion
GENOCEA BIOSCIENCES, INC.
Common Stock
2014-02-10+178,732→ 262,765 total
Exercise of In-Money
GENOCEA BIOSCIENCES, INC.
Common Stock
2014-02-10+15,852→ 1,682,037 total
Conversion
GENOCEA BIOSCIENCES, INC.
Common Stock
2014-02-10+428,502→ 1,666,185 total
Conversion
GENOCEA BIOSCIENCES, INC.
Series B Preferred Stock
2014-02-10−3,207,794→ 0 total
Conversion
GENOCEA BIOSCIENCES, INC.
Common Stock
2014-02-10+705,357→ 968,122 total
Conversion
GENOCEA BIOSCIENCES, INC.
Seed Preferred Stock
2014-02-10−2,126,923→ 0 total
Conversion
GENOCEA BIOSCIENCES, INC.
Series C Preferred Stock
2014-02-10−5,099,196→ 0 total
Exercise of In-Money
GENOCEA BIOSCIENCES, INC.
Warrants to purchase Series A Preferred Stock
2014-02-10−587,931→ 0 total

Companies

Recent Filings

Address

295 MADISON AVENUE, 24TH FLOOR

NEW YORK, NY, 10017

View on SEC.gov